Laboratory monitoring of new anticoagulants

Area of Science:

• Hematology
• Clinical Chemistry
• Pharmacology

Background:

• Maintaining hemostasis requires a delicate balance between bleeding and clotting.
• Coagulation disorders can lead to significant morbidity and mortality.
• Anticoagulant therapy is essential but requires precise monitoring to prevent complications.

Purpose of the Study:

• To highlight the importance of anticoagulant monitoring in managing coagulation disorders.
• To discuss the challenges and pitfalls of current laboratory monitoring tests for new anticoagulants.
• To explore the role of laboratory testing in transitioning patients to warfarin therapy.

Main Methods:

• Review of existing literature on anticoagulant monitoring.
• Discussion of new anticoagulant drugs, including direct thrombin inhibitors (DTIs) and Factor Xa inhibitors.
• Analysis of limitations of current laboratory tests and investigation of newer alternatives.

Main Results:

• Newer anticoagulants like DTIs (argatroban, bivalirudin, hirudin) and fondaparinux present monitoring challenges.
• Existing laboratory tests may have limitations when used with these novel agents.
• Alternative laboratory monitoring tests have been investigated to address these limitations.

Conclusions:

• Effective management of coagulation disorders necessitates rigorous anticoagulant monitoring.
• Careful selection and interpretation of laboratory tests are vital for patients on new anticoagulants.
• Laboratory testing plays a key role in facilitating safe transitions between anticoagulant therapies.